Adamas Pharmaceuticals (ADMS) Tops Q4 EPS by 5c

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 10/29/2026

1. NOW
2. GOOGL
3. MSFT
4. ENPH
5. SPY
6. GOOG
7. BA
8. HOOD
9. NXPI
10. STX

Go back to Adamas Pharmaceuticals (ADMS) Tops Q4 EPS by 5c

Adamas Reports First Quarter 2015 Financial Results

May 13, 2015 4:00 PM EDT

EMERYVILLE, Calif., May 13, 2015 (GLOBE NEWSWIRE) -- Adamas Pharmaceuticals, Inc. (Nasdaq: ADMS) today reported financial results for the first quarter of 2015.

"In 2015, we have made continued progress throughout our business, including receiving orphan drug designation for our lead product candidate, ADS-5102, for the treatment of levodopa-induced dyskinesia (LID), a complication associated with the treatment of Parkinson's disease and further increasing our patent estate," said Gregory T. Went, Ph.D., Chairman and CEO of Adamas Pharmaceuticals, Inc. "In the coming months, we look forward to expanding our wholly-owned product pipeline with the... More